Copyright Reports & Markets. All rights reserved.

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Research Report 2022

Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
  • 1.2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
  • 1.2.2 Oral
  • 1.2.3 Intravenous Injection
  • 1.2.4 Intramuscular Injection
  • 1.3 Market by Application
  • 1.3.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Application: 2017 VS 2021 VS 2028
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Global Growth Trends

    • 2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Perspective (2017-2028)
    • 2.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Growth Trends by Region
    • 2.2.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Region (2017-2022)
  • 2.2.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Region (2023-2028)
  • 2.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
  • 2.3.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Industry Trends
  • 2.3.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Drivers
  • 2.3.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Challenges
  • 2.3.4 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Restraints
  • 3 Competition Landscape by Key Players

    • 3.1 Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Revenue
    • 3.1.1 Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Revenue (2017-2022)
  • 3.1.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Players (2017-2022)
  • 3.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue
  • 3.4 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Concentration Ratio
  • 3.4.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in 2021
  • 3.5 Acute Respiratory Distress Syndrome (ARDS) Treatment Key Players Head office and Area Served
  • 3.6 Key Players Acute Respiratory Distress Syndrome (ARDS) Treatment Product Solution and Service
  • 3.7 Date of Enter into Acute Respiratory Distress Syndrome (ARDS) Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans
  • 4 Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Type

    • 4.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Type (2017-2022)
    • 4.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Type (2023-2028)

    5 Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Application

    • 5.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Application (2017-2022)
    • 5.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Application (2023-2028)

    6 North America

    • 6.1 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2017-2028)
    • 6.2 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2017-2022)
    • 6.3 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2023-2028)
    • 6.4 United States
    • 6.5 Canada

    7 Europe

    • 7.1 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2017-2028)
    • 7.2 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2017-2022)
    • 7.3 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2023-2028)
    • 7.4 Germany
    • 7.5 France
    • 7.6 U.K.
    • 7.7 Italy
    • 7.8 Russia
    • 7.9 Nordic Countries

    8 Asia-Pacific

    • 8.1 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2017-2028)
    • 8.2 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2017-2022)
    • 8.3 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2023-2028)
    • 8.4 China
    • 8.5 Japan
    • 8.6 South Korea
    • 8.7 Southeast Asia
    • 8.8 India
    • 8.9 Australia

    9 Latin America

    • 9.1 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2017-2028)
    • 9.2 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2017-2022)
    • 9.3 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2023-2028)
    • 9.4 Mexico
    • 9.5 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2017-2028)
    • 10.2 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2017-2022)
    • 10.3 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2023-2028)
    • 10.4 Turkey
    • 10.5 Saudi Arabia
    • 10.6 UAE

    11 Key Players Profiles

    • 11.1 Gilead Sciences Inc.
    • 11.1.1 Gilead Sciences Inc. Company Detail
  • 11.1.2 Gilead Sciences Inc. Business Overview
  • 11.1.3 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.1.4 Gilead Sciences Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.1.5 Gilead Sciences Inc. Recent Development
  • 11.2 Terumo Corporation
  • 11.2.1 Terumo Corporation Company Detail
  • 11.2.2 Terumo Corporation Business Overview
  • 11.2.3 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.2.4 Terumo Corporation Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.2.5 Terumo Corporation Recent Development
  • 11.3 Getinge Ab
  • 11.3.1 Getinge Ab Company Detail
  • 11.3.2 Getinge Ab Business Overview
  • 11.3.3 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.3.4 Getinge Ab Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.3.5 Getinge Ab Recent Development
  • 11.4 Livanova Plc
  • 11.4.1 Livanova Plc Company Detail
  • 11.4.2 Livanova Plc Business Overview
  • 11.4.3 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.4.4 Livanova Plc Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.4.5 Livanova Plc Recent Development
  • 11.5 Medtronic
  • 11.5.1 Medtronic Company Detail
  • 11.5.2 Medtronic Business Overview
  • 11.5.3 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.5.4 Medtronic Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.5.5 Medtronic Recent Development
  • 11.6 Alung Technologies, Inc.
  • 11.6.1 Alung Technologies, Inc. Company Detail
  • 11.6.2 Alung Technologies, Inc. Business Overview
  • 11.6.3 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.6.4 Alung Technologies, Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.6.5 Alung Technologies, Inc. Recent Development
  • 11.7 Armstrong Medical
  • 11.7.1 Armstrong Medical Company Detail
  • 11.7.2 Armstrong Medical Business Overview
  • 11.7.3 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.7.4 Armstrong Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.7.5 Armstrong Medical Recent Development
  • 11.8 Besmed Health Business Corp.
  • 11.8.1 Besmed Health Business Corp. Company Detail
  • 11.8.2 Besmed Health Business Corp. Business Overview
  • 11.8.3 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.8.4 Besmed Health Business Corp. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.8.5 Besmed Health Business Corp. Recent Development
  • 11.9 Dragerwerk Ag & Co. Kgaa
  • 11.9.1 Dragerwerk Ag & Co. Kgaa Company Detail
  • 11.9.2 Dragerwerk Ag & Co. Kgaa Business Overview
  • 11.9.3 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.9.4 Dragerwerk Ag & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.9.5 Dragerwerk Ag & Co. Kgaa Recent Development
  • 11.10 Eurosets
  • 11.10.1 Eurosets Company Detail
  • 11.10.2 Eurosets Business Overview
  • 11.10.3 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.10.4 Eurosets Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.10.5 Eurosets Recent Development
  • 11.11 F. Hoffmann-la Roche Ltd.
  • 11.11.1 F. Hoffmann-la Roche Ltd. Company Detail
  • 11.11.2 F. Hoffmann-la Roche Ltd. Business Overview
  • 11.11.3 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.11.4 F. Hoffmann-la Roche Ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.11.5 F. Hoffmann-la Roche Ltd. Recent Development
  • 11.12 Fisher & Paykel Healthcare Limited
  • 11.12.1 Fisher & Paykel Healthcare Limited Company Detail
  • 11.12.2 Fisher & Paykel Healthcare Limited Business Overview
  • 11.12.3 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.12.4 Fisher & Paykel Healthcare Limited Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.12.5 Fisher & Paykel Healthcare Limited Recent Development
  • 11.13 Fresenius Se & Co. Kgaa
  • 11.13.1 Fresenius Se & Co. Kgaa Company Detail
  • 11.13.2 Fresenius Se & Co. Kgaa Business Overview
  • 11.13.3 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.13.4 Fresenius Se & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.13.5 Fresenius Se & Co. Kgaa Recent Development
  • 11.14 Hamilton Medical
  • 11.14.1 Hamilton Medical Company Detail
  • 11.14.2 Hamilton Medical Business Overview
  • 11.14.3 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.14.4 Hamilton Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.14.5 Hamilton Medical Recent Development
  • 11.15 Nice Neotech Medical Systems Pvt.ltd.
  • 11.15.1 Nice Neotech Medical Systems Pvt.ltd. Company Detail
  • 11.15.2 Nice Neotech Medical Systems Pvt.ltd. Business Overview
  • 11.15.3 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.15.4 Nice Neotech Medical Systems Pvt.ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.15.5 Nice Neotech Medical Systems Pvt.ltd. Recent Development
  • 11.16 Nipro
  • 11.16.1 Nipro Company Detail
  • 11.16.2 Nipro Business Overview
  • 11.16.3 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.16.4 Nipro Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.16.5 Nipro Recent Development
  • 11.17 Pfizer Inc.
  • 11.17.1 Pfizer Inc. Company Detail
  • 11.17.2 Pfizer Inc. Business Overview
  • 11.17.3 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.17.4 Pfizer Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.17.5 Pfizer Inc. Recent Development
  • 11.18 Resmed
  • 11.18.1 Resmed Company Detail
  • 11.18.2 Resmed Business Overview
  • 11.18.3 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.18.4 Resmed Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.18.5 Resmed Recent Development
  • 11.19 Smiths Medical
  • 11.19.1 Smiths Medical Company Detail
  • 11.19.2 Smiths Medical Business Overview
  • 11.19.3 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.19.4 Smiths Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.19.5 Smiths Medical Recent Development
  • 11.20 Weinmann Emergency Medical Technology Gmbh+co. Kg
  • 11.20.1 Weinmann Emergency Medical Technology Gmbh+co. Kg Company Detail
  • 11.20.2 Weinmann Emergency Medical Technology Gmbh+co. Kg Business Overview
  • 11.20.3 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
  • 11.20.4 Weinmann Emergency Medical Technology Gmbh+co. Kg Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2017-2022)
  • 11.20.5 Weinmann Emergency Medical Technology Gmbh+co. Kg Recent Development
  • 12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
    • 13.2 Disclaimer
    • Industry Insights
      The global Acute Respiratory Distress Syndrome (ARDS) Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

      Fully considering the economic change by this health crisis, Oral accounting for % of the Acute Respiratory Distress Syndrome (ARDS) Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.

      China Acute Respiratory Distress Syndrome (ARDS) Treatment market size is valued at US$ million in 2021, while the North America and Europe Acute Respiratory Distress Syndrome (ARDS) Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Acute Respiratory Distress Syndrome (ARDS) Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

      With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acute Respiratory Distress Syndrome (ARDS) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Acute Respiratory Distress Syndrome (ARDS) Treatment market in terms of revenue.

      Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Acute Respiratory Distress Syndrome (ARDS) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Acute Respiratory Distress Syndrome (ARDS) Treatment market.

      Impact of Covid-19 Outbreak

      This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

      Segmental Analysis

      The report has been segmented into product and application segments. The researchers have documented all the products present today in the Acute Respiratory Distress Syndrome (ARDS) Treatment market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

      Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Type

      Oral

      Intravenous Injection

      Intramuscular Injection

      Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Application

      Hospital Pharmacy

      Retail Pharmacy

      Online Pharmacy

      Regional Analysis

      North America

      United States

      Canada

      Europe

      Germany

      France

      UK

      Italy

      Russia

      Nordic Countries

      Rest of Europe

      Asia-Pacific

      China

      Japan

      South Korea

      Southeast Asia

      India

      Australia

      Rest of Asia

      Latin America

      Mexico

      Brazil

      Rest of Latin America

      Middle East & Africa

      Turkey

      Saudi Arabia

      UAE

      Rest of MEA

      Competitive Landscape

      This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

      Gilead Sciences Inc.

      Terumo Corporation

      Getinge Ab

      Livanova Plc

      Medtronic

      Alung Technologies, Inc.

      Armstrong Medical

      Besmed Health Business Corp.

      Dragerwerk Ag & Co. Kgaa

      Eurosets

      F. Hoffmann-la Roche Ltd.

      Fisher & Paykel Healthcare Limited

      Fresenius Se & Co. Kgaa

      Hamilton Medical

      Nice Neotech Medical Systems Pvt.ltd.

      Nipro

      Pfizer Inc.

      Resmed

      Smiths Medical

      Weinmann Emergency Medical Technology Gmbh+co. Kg

      Frequently Asked Questions

      What factors will challenge the Acute Respiratory Distress Syndrome (ARDS) Treatment market growth?

      Which end-use segment will expand at the fastest CAGR in the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      Which are the emerging players in the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      How concentrated is the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      Which factors are positively contributing to the Acute Respiratory Distress Syndrome (ARDS) Treatment market growth?

      Which are the novel product innovations in the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      Which product segment will emerge as the most lucrative in the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      Which factors are increasing the competition in the Acute Respiratory Distress Syndrome (ARDS) Treatment market?

      Which are the strategic measures taken by the Acute Respiratory Distress Syndrome (ARDS) Treatment industry players?

      Which region will witness inactive growth during the forecast period?

      What key trends are likely to emerge in the Acute Respiratory Distress Syndrome (ARDS) Treatment market in the coming years?

      Buy now